Drugs / Ondansetron
Ondansetron
also known as
Zofran · Ondalenz · ondansetron hydrochloride · Ondansetron HCl · BEKINDA · Ondansetron (Zofran) · Zofran (ondansetron hydrochloride) · Zofran ODT · +30 more
Other / unclassified targets HTR3A via inhibition
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (9) | US (FDA) | ZOFRAN | — | 1993-02-02 – 2005-03-25 | fda.gov ↗ |
| Approved | US (FDA) | ZOFRAN | — | 1991-01-04 | fda.gov ↗ |
Trials 187 · started per year
today
US approved 1991
2
2
3
6
8
5
7
2
4
12
7
7
7
7
6
8
9
6
6
9
7
9
8
4
9
11
7
9
199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT05819619 | Jul 2023 → Apr 2024 | — | Hackensack Meridian Health | Terminated | No outcome recorded |
| Phase 0 | NCT04891484 | Apr 2021 → Apr 2022 | nephrolithiasis | Mansoura University | Completed | No outcome recorded |
| Phase 0 | NCT03125811 | Jul 2017 → Mar 2023 | — | Texas Tech University Health Sciences Center, El Paso | Completed | No outcome recorded |
| Phase 0 | NCT01851993 | Jun 2013 → Sep 2014 | — | McGill University | Completed | No outcome recorded |
| Phase 128 trials | ||||||
| Phase 1 | NCT07310563 | Dec 2024 → May 2025 | obesity disorder | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT06297499 | Aug 2024 → Aug 2025 overdue | — | Wayne State University | Recruiting | No outcome recorded |
| Phase 1 | NCT05124067 | Oct 2021 → Jan 2022 | delirium | Tanta University | Completed | No outcome recorded |
| Phase 1 | NCT03809234 | May 2019 → Nov 2020 | neuropathy, painful | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT03583489 | Jul → Aug 2018 | — | Acacia Pharma Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02614586 | Dec 2015 → Apr 2016 | schizophrenia | Takeda | Terminated | No outcome recorded |
| Phase 1 | NCT02460341 | Aug 2015 → Feb 2017 | — | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 1 | NCT02473887 | Sep 2014 → Jan 2015 | gastroenteritis | Hamad Medical Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01815125 | Mar 2013 → Feb 2014 | traumatic brain injury | St. Justine's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01572012 | Feb 2012 → Nov 2013 | — | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01290276 | Dec 2010 → Aug 2012 | — | Tong Lee | Completed | No outcome recorded |
| Phase 1 | NCT00905190 | Feb → Mar 2009 | — | Forest Laboratories | Completed | No outcome recorded |
| Phase 1 | NCT01036854 | Feb → Apr 2009 | — | Forest Laboratories | Completed | No outcome recorded |
| Phase 1 | NCT00981487 | Feb → Mar 2009 | — | Forest Laboratories | Completed | No outcome recorded |
| Phase 1 | NCT01113164 | Sep 2008 → Feb 2012 | alcohol dependence | Brown University | Completed | No outcome recorded |
| Phase 1 | NCT01220167 | Aug 2008 | — | Aquestive Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00437229 | Feb → May 2007 | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00649363 | Jul 2005 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00947128 | Sep → Oct 2004 | — | Sandoz | Completed | No outcome recorded |
| Phase 1 | NCT00946387 | Sep 2004 | — | Sandoz | Completed | No outcome recorded |
| Phase 1 | NCT00659685 | Nov 2003 → ? | — | Par Pharmaceutical, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00659074 | Oct 2003 → Jan 2004 | — | Par Pharmaceutical, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00648583 | Jul 2003 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00649532 | Jul 2003 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00934921 | Feb 2003 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00934180 | Dec 2002 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00654277 | Aug → Sep 2002 | — | Par Pharmaceutical, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00653458 | Aug → Sep 2002 | — | Par Pharmaceutical, Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04603066 | Jan 2021 → Oct 2023 | neuropathy, painful | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT01217190 | Sep 2008 | chemotherapy-induced toxicity | MonoSol Rx | Completed | No outcome recorded |
| Phase 233 trials | ||||||
| Phase 2 | NCT07381634 | Mar → Dec 2026 expected | hepatocellular carcinoma | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04226170 | Nov 2023 → Apr 2025 | AChR+ myasthenia gravis | DAS-MG, Inc | Terminated | No outcome recorded |
| Phase 2 | NCT05378113 | May → Aug 2023 | — | Emory University | Terminated | No outcome recorded |
| Phase 2 | NCT05342818 | Apr → Jul 2022 | gastroparesis | Tanta University | Completed | No outcome recorded |
| Phase 2 | NCT05202574 | Sep 2021 → Feb 2022 | intracranial hypotension | Minia University | Unknown | No outcome recorded |
| Phase 2 | NCT04557189 | Oct 2020 → Mar 2022 | — | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT06289335 | Aug 2020 → Sep 2021 | — | Hospital Central "Dr. Ignacio Morones Prieto" | Completed | No outcome recorded |
| Phase 2 | NCT04468685 | Jul → Dec 2020 | cholecystitis | National Hepatology & Tropical Medicine Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT03865290 | Apr 2019 → Mar 2028 expected | diabetes mellitus, dyspepsia | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT03785691 | Mar 2019 → Jul 2022 | hyperemesis gravidarum | Nordsjaellands Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT04362449 | Jan 2019 → Feb 2023 | gallbladder cancer | Imperial College Healthcare NHS Trust | Unknown | No outcome recorded |
| Phase 2 | NCT03572829 | Mar 2018 → Jan 2020 | chemotherapy-induced toxicity, head and neck squamous cell carcinoma | Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02757105 | May 2016 → Jun 2017 | irritable bowel syndrome | RedHill Biopharma Limited | Completed | No outcome recorded |
| Phase 2 | NCT00890149 | Sep 2015 → Sep 2016 | alcohol abuse, alcohol dependence | University of Maryland, Baltimore | Terminated | No outcome recorded |
| Phase 2 | NCT02354703 | Aug 2015 → Mar 2020 | alcohol-related disorders | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 2 | NCT01965704 | Sep 2014 → Sep 2020 | drug dependence, neonatal abstinence syndrome | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT02006056 | Nov 2013 → Jun 2014 | — | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 2 | NCT01841606 | Mar → Dec 2013 | — | University of British Columbia | Completed | No outcome recorded |
| Phase 2 | NCT01370408 | Feb 2012 → Mar 2016 | chemotherapy-induced toxicity | Northside Hospital, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01275248 | Jan 2011 → Sep 2015 | obsessive-compulsive disorder | Transcept Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01254877 | Dec 2010 → Jan 2017 | alcohol abuse, alcohol dependence | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT00795769 | Aug 2008 → Jun 2009 | Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, acute myeloid leukemia with 11q23 abnormalities +29 | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00689572 | Jul 2008 → Dec 2013 | cocaine dependence | University of Virginia | Completed | No outcome recorded |
| Phase 2 | NCT01543945 | Mar 2008 → Dec 2011 | — | Prince of Songkla University | Completed | No outcome recorded |
| Phase 2 | NCT00678457 | Jan 2007 → May 2008 | alcohol dependence | University of Virginia | Completed | No outcome recorded |
| Phase 2 | NCT00285051 | Nov 2005 → Feb 2009 | cancer | Rafa Laboratories | Terminated | No outcome recorded |
| Phase 2 | NCT00183222 | May → Dec 2005 | alcohol dependence | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2 | NCT00006205 | Mar 2005 → Jun 2013 | alcohol dependence | Bankole Johnson | Unknown | No outcome recorded |
| Phase 2 | NCT00040053 | Jun 2002 → Feb 2004 | methamphetamine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00027079 | Sep 2001 → Aug 2004 | alcohol dependence | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 2 | NCT00033085 | May 2001 → Dec 2002 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000289 | May 1998 → Dec 2001 | nicotine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 2 | NCT00000443 | ? → Apr 2000 | alcohol dependence | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT07588217 | Oct 2026 → Oct 2028 expected | acute lung injury, acute respiratory distress syndrome | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT03052361 | Jul 2017 → Sep 2020 | gastroenteritis | St. Justine's Hospital | Terminated | No outcome recorded |
| Phase 2/3 | NCT01591291 | Jun 2012 → Dec 2017 | alcohol dependence | University of Virginia | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT01414777 | Nov 2009 → Jun 2011 | hypotensive disorder, pregnancy disorder | University of Virginia | Completed | No outcome recorded |
| Phase 327 trials | ||||||
| Phase 3 | NCT05876585 | Jun 2025 overdue | gastroenteritis | Genuine Research Center, Egypt | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06282211 | Feb → Mar 2024 | — | The First Affiliated Hospital of Xinxiang Medical College | Unknown | No outcome recorded |
| Phase 3 | NCT06208917 | Jul 2023 → Jul 2026 overdue | childhood neoplasm | Yizhuo Zhang | Recruiting | No outcome recorded |
| Phase 3 | NCT05872893 | Jun 2023 → Jan 2025 | childhood malignant neoplasm | Immune Oncology Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT05620641 | Oct 2022 → Feb 2025 | morbid obesity | Tanta University | Completed | No outcome recorded |
| Phase 3 | NCT04703088 | Jun → Aug 2021 | hypotensive disorder | Laval University | Unknown | No outcome recorded |
| Phase 3 | NCT05087615 | Mar → Aug 2021 | — | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT04101227 | Feb 2020 → Feb 2022 | alcohol-related disorders | Adial Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03817970 | Nov 2019 → Sep 2027 expected | cisplatin toxicity | University of Colorado, Denver | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03851835 | Sep 2019 → Jun 2024 | diarrheal disease, gastroenteritis, viral infectious disease | University of Calgary | Completed | No outcome recorded |
| Phase 3 | NCT03555188 | Mar 2018 → Aug 2020 | irritable bowel syndrome | University of Leeds | Completed | No outcome recorded |
| Phase 3 | NCT03330119 | Oct 2017 → Jun 2018 | pregnancy disorder, substance-related disorder | Brest, Norman A., M.D. | Terminated | No outcome recorded |
| Phase 3 | NCT02619201 | Nov 2015 → May 2016 | gastroenteritis | Hospital General Naval de Alta Especialidad - Escuela Medico Naval | Unknown | No outcome recorded |
| Phase 3 | NCT02246439 | Dec 2014 → Feb 2017 | gastritis, gastroenteritis | RedHill Biopharma Limited | Completed | No outcome recorded |
| Phase 3 | NCT02028910 | Jan → Oct 2014 | gastroenteritis | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 3 | NCT01536392 | Mar 2012 → Oct 2019 | cervical cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT01432977 | Sep 2011 → Jun 2012 | pain agnosia | University Hospital, Limoges | Completed | No outcome recorded |
| Phase 3 | NCT01257672 | Jul 2011 → Nov 2013 | gastroenteritis | IRCCS Burlo Garofolo | Completed | No outcome recorded |
| Phase 3 | NCT00768508 | Sep 2008 → Dec 2012 | alcohol dependence | Bankole Johnson | Completed | No outcome recorded |
| Phase 3 | NCT00382642 | Jun 2006 → Mar 2009 | alcohol dependence | Bankole Johnson | Completed | No outcome recorded |
| Phase 3 | NCT00147355 | Nov 2005 → Nov 2008 | HIV infectious disease | Kirby Institute | Terminated | No outcome recorded |
| Phase 3 | NCT00149734 | Jan 2005 → May 2010 | schizophrenia | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 3 | NCT00090246 | May 2004 → Apr 2005 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00090155 | Sep 2003 → Nov 2004 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00642512 | Jul 2003 → Jul 2004 | chemotherapy-induced toxicity | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00020657 | Jul 2001 → Oct 2004 | cancer of unknown primary site | Gary Morrow | Completed | No outcome recorded |
| Phase 3 | NCT00006348 | Oct 2000 → Sep 2001 | childhood malignant neoplasm, leukemia, myelodysplastic syndrome, myeloproliferative neoplasm +3 | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 443 trials | ||||||
| Phase 4 | NCT07681076 | Aug → Nov 2026 expected | — | Karuna Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07638527 | Jul 2026 → Feb 2027 expected | — | Faisalabad Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07336680 | Jan → May 2026 overdue | — | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06632184 | Dec 2025 → Mar 2026 overdue | — | Mexican Social Security Institute | Active not recruiting | No outcome recorded |
| Phase 4 | NCT07264738 | Jul → Sep 2025 overdue | — | Peking Union Medical College Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05844501 | Apr 2025 → Dec 2027 expected | atrial fibrillation | Indiana University | Recruiting | No outcome recorded |
| Phase 4 | NCT07217600 | Mar 2025 → Mar 2026 overdue | childhood malignant neoplasm, radiation-induced disorder | Chongqing University Cancer Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06747975 | Jan 2025 → Jan 2026 overdue | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06729307 | Jan 2025 → Jan 2026 overdue | — | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06704139 | Dec 2024 → Dec 2026 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06697782 | Jul → Dec 2024 | thyroid cancer | The First Affiliated Hospital of Zhengzhou University | Completed | No outcome recorded |
| Phase 4 | NCT05583214 | Oct → Dec 2022 | — | Muhammad Mubariz | Unknown | No outcome recorded |
| Phase 4 | NCT05127876 | Jan → Mar 2022 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT04318847 | Oct 2021 → Apr 2023 | — | Lizar Aguirre Pascasio | Unknown | No outcome recorded |
| Phase 4 | NCT05439772 | Jan 2021 → Jul 2023 | diarrheal disease, eosinophilic gastroenteritis, inflammatory bowel disease | State University of New York - Downstate Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT06927817 | Nov 2020 → Nov 2021 | cholecystitis | University of Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT03833999 | Oct 2018 → Jun 2019 | intestinal motility disease | University of Nottingham | Completed | No outcome recorded |
| Phase 4 | NCT07068230 | Oct 2018 → Sep 2019 | headache disorder | Minia University | Completed | No outcome recorded |
| Phase 4 | NCT03503292 | May 2018 → Dec 2019 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT03262038 | Dec 2017 → Aug 2019 | — | University of Michigan | Terminated | No outcome recorded |
| Phase 4 | NCT03297021 | Oct 2017 → Apr 2019 | — | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 4 | NCT03035942 | Jan 2017 → Oct 2018 | disease of bone structure, poisoning | Pontifical Catholic University of São Paulo | Completed | No outcome recorded |
| Phase 4 | NCT02928601 | Nov 2016 → Aug 2017 | — | Cukurova University | Completed | No outcome recorded |
| Phase 4 | NCT02468323 | Oct 2015 → Feb 2017 | — | Hospital de Base | Completed | No outcome recorded |
| Phase 4 | NCT02541019 | Oct 2015 → Jan 2017 | — | Bonsucesso Federal Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02803788 | Jul 2015 → Jul 2016 | — | Government Medical College, Haldwani | Unknown | No outcome recorded |
| Phase 4 | NCT01870648 | May 2014 → Dec 2017 | diarrheal disease, gastroenteritis | Dr. Stephen Freedman | Completed | No outcome recorded |
| Phase 4 | NCT01870635 | May 2014 → Jan 2017 | diarrheal disease, gastroenteritis | Dr. Stephen Freedman | Completed | No outcome recorded |
| Phase 4 | NCT02985840 | Jan 2014 → Nov 2016 | — | OhioHealth | Terminated | No outcome recorded |
| Phase 4 | NCT01876290 | May 2013 → Jan 2014 | — | Hopital Foch | Completed | No outcome recorded |
| Phase 4 | NCT02382146 | Apr 2012 → Dec 2014 | — | Yeditepe University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01913990 | Sep 2011 → Aug 2017 | — | Ottawa Hospital Research Institute | Unknown | No outcome recorded |
| Phase 4 | NCT01050270 | Sep 2010 → Dec 2012 | poisoning | University of Edinburgh | Completed | No outcome recorded |
| Phase 4 | NCT01303536 | Dec 2009 → Mar 2010 | obsessive-compulsive disorder | Institute of Neuroscience, Florence, Italy | Completed | No outcome recorded |
| Phase 4 | NCT00878228 | Apr 2009 → Jan 2010 | — | Hospital for Special Surgery, New York | Completed | No outcome recorded |
| Phase 4 | NCT00745004 | Jan 2009 → Jul 2011 | irritable bowel syndrome | University of Nottingham | Completed | No outcome recorded |
| Phase 4 | NCT00793663 | Nov 2008 → Apr 2011 | — | RWTH Aachen University | Completed | No outcome recorded |
| Phase 4 | NCT01165866 | Jun → Dec 2008 | gastroenteritis | Hamad Medical Corporation | Completed | No outcome recorded |
| Phase 4 | NCT00796497 | Mar → Nov 2008 | obsessive-compulsive disorder | Institute of Neuroscience, Florence, Italy | Completed | No outcome recorded |
| Phase 4 | NCT00674713 | Jan 2006 → Sep 2007 | cholelithiasis | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| Phase 4 | NCT00090207 | Jan → Sep 2004 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00429832 | Oct 2003 → Nov 2005 | — | University of New Mexico | Completed | No outcome recorded |
| Phase 4 | NCT00092183 | Oct 2002 → Dec 2003 | breast cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase not applicable46 trials | ||||||
| — | NCT07632144 | Jun → Jul 2026 overdue | — | Mongi Slim Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07511491 | Apr → Aug 2026 overdue | — | Tanta University | Recruiting | No outcome recorded |
| — | NCT07489742 | Mar → Sep 2026 expected | — | Tanta University | Recruiting | No outcome recorded |
| — | NCT07377903 | Feb → Jul 2026 overdue | — | Sohag University | Not yet recruiting | No outcome recorded |
| — | NCT06898268 | Jul → Dec 2024 | gastroesophageal reflux disease | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT06423820 | May 2024 → Jan 2025 | strabismus | Tanta University | Completed | No outcome recorded |
| — | NCT06423807 | May → Sep 2024 | benign shuddering attacks | Tanta University | Completed | No outcome recorded |
| — | NCT06371014 | May → Dec 2024 | — | Shanghai Children's Medical Center | Unknown | No outcome recorded |
| — | NCT06300346 | Mar → Aug 2024 | — | Sohag University | Unknown | No outcome recorded |
| — | NCT06254131 | Feb → Oct 2024 | — | Tanta University | Completed | No outcome recorded |
| — | NCT06080880 | Dec 2023 → Nov 2025 overdue | chemotherapy-induced toxicity | Hubei Cancer Hospital | Recruiting | No outcome recorded |
| — | NCT06444737 | Nov 2023 → Jun 2024 | intracranial hypotension | Mongi Slim Hospital | Unknown | No outcome recorded |
| — | NCT06175806 | Sep → Nov 2023 | — | Ain Shams University | Completed | No outcome recorded |
| — | NCT05475873 | Jun → Oct 2023 | — | General Hospital of Ningxia Medical University | Completed | No outcome recorded |
| — | NCT04499274 | Sep 2020 → Nov 2023 | blood coagulation disease | Seoul National University Bundang Hospital | Unknown | No outcome recorded |
| — | NCT05076461 | Jul 2020 → Jun 2021 | gastroenteritis | Tehsil Headquarter Hospital | Completed | No outcome recorded |
| — | NCT04294992 | Apr → Sep 2020 | — | Kasr El Aini Hospital | Unknown | No outcome recorded |
| — | NCT07334223 | Jan → Jun 2020 | benign shuddering attacks | Mayo Hospital Lahore | Completed | No outcome recorded |
| — | NCT04169828 | Aug 2019 → Jan 2025 | juvenile idiopathic arthritis | University of British Columbia | Completed | No outcome recorded |
| — | NCT03859102 | Dec 2018 → Oct 2019 | aneurysm or dilatation of ascending aorta, aortic valve disorder, cardiac valvular defect, coronary artery disorder +2 | James Cook University Hospital | Unknown | No outcome recorded |
| — | NCT02966041 | Mar → Jul 2018 | — | University of British Columbia | Completed | No outcome recorded |
| — | NCT05590936 | Jan 2018 → Dec 2022 | — | University of Thessaly | Completed | No outcome recorded |
| — | NCT03182179 | Nov 2016 → Nov 2021 | rectal cancer | Ente Ospedaliero Cantonale, Bellinzona | Completed | No outcome recorded |
| — | NCT02901054 | Aug → Nov 2016 | — | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT02793843 | Jun 2016 → Jun 2017 | — | Makassed General Hospital | Completed | No outcome recorded |
| — | NCT02883192 | Feb → Oct 2016 | — | Bnai Zion Medical Center | Unknown | No outcome recorded |
| — | NCT02862873 | Mar → May 2015 | hypotensive disorder | Centre Hospitalier Universitaire Dijon | Terminated | No outcome recorded |
| — | NCT03685032 | Aug 2014 → Feb 2016 | — | Khon Kaen University | Completed | No outcome recorded |
| — | NCT02026778 | Dec 2013 → Nov 2014 | — | Yonsei University | Completed | No outcome recorded |
| — | NCT01668069 | Oct 2012 | hyperemesis gravidarum | United States Naval Medical Center, San Diego | Completed | No outcome recorded |
| — | NCT01843868 | Jan 2012 → Jun 2015 | non-Hodgkin lymphoma | Australasian Leukaemia and Lymphoma Group | Withdrawn | No outcome recorded |
| — | NCT01477242 | Nov 2011 → May 2012 | — | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT01549652 | Apr 2011 → Apr 2015 | drug dependence, substance withdrawal syndrome | Stanford University | Completed | No outcome recorded |
| — | NCT01640340 | Jan → Aug 2011 | cancer | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| — | NCT01006707 | Nov 2010 → Jul 2013 | substance-related disorder | Stanford University | Completed | No outcome recorded |
| — | NCT01759706 | Oct 2010 → Dec 2012 | pancreatic neoplasm | Vita-Salute San Raffaele University | Completed | No outcome recorded |
| — | NCT01169805 | Aug 2010 → Jun 2011 | non-congenital cyst of kidney | Yonsei University | Completed | No outcome recorded |
| — | NCT01067677 | Feb 2010 → Feb 2012 | — | Franklyn Cladis | Withdrawn | No outcome recorded |
| — | NCT01216410 | Dec 2008 → Apr 2011 | — | Duke University | Completed | No outcome recorded |
| — | NCT00695864 | May 2008 → Jul 2009 | substance withdrawal syndrome | Stanford University | Completed | No outcome recorded |
| — | NCT00599573 | Oct 2007 → Jul 2010 | HIV infectious disease, cocaine dependence | University of Virginia | Unknown | No outcome recorded |
| — | NCT00499668 | Aug 2007 → Jan 2008 | leukemia, lymphoproliferative syndrome, myelodysplastic syndrome, myeloproliferative neoplasm +1 | Vanderbilt-Ingram Cancer Center | Withdrawn | No outcome recorded |
| — | NCT00199329 | Jan 2005 → ? | — | Khon Kaen University | Completed | No outcome recorded |
| — | NCT00120744 | Jan 2004 → Apr 2005 | diarrheal disease, gastroenteritis | The Hospital for Sick Children | Completed | No outcome recorded |
| — | NCT00387556 | Dec 2002 → Dec 2006 | — | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT00018850 | Jun 1998 → Jun 2003 | schizophrenia | US Department of Veterans Affairs | Completed | No outcome recorded |
Also used as a comparator or background therapy in 267 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT07662200 Comparator | Aug 2026 → Aug 2027 expected | malignant germ cell tumor | Ottawa Hospital Research Institute | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT04682743 Comparator | Jan 2021 → Jan 2022 | — | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT03593811 Comparator | Aug 2018 → Apr 2021 | — | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT03475693 Background | Sep 2017 → Nov 2019 | traumatic encephalopathy | Corewell Health South | Completed | No outcome recorded |
| Phase 0 | NCT00314743 Background | Oct 2005 → Dec 2008 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 115 trials | ||||||
| Phase 1 | NCT07697625 Background | Jul → Sep 2026 expected | — | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07603596 Background | May 2026 → Apr 2028 expected | delirium, digestive system neoplasm | Qianfoshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07201883 Comparator | Aug 2025 → Feb 2026 overdue | — | Makassed General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05742256 Background | Mar 2023 → Jul 2024 | — | Qianfoshan Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT05035407 Background | Mar 2022 → Jul 2025 | — | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT03973047 Comparator | Jun → Jul 2019 | — | AMAG Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03747341 Background | Mar 2018 → Jan 2019 | substance-related disorder | Indivior Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02648490 Background | Sep 2016 → Jun 2019 | cancer | Henlix, Inc | Completed | No outcome recorded |
| Phase 1 | NCT01449188 Comparator | Aug → Dec 2011 | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01111851 Background | Apr → Oct 2010 | chemotherapy-induced toxicity | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00929955 Comparator | Jun → Sep 2009 | schizoaffective disorder, schizophrenia, schizophreniform disorder | Pakistan Institute of Living and Learning | Completed | No outcome recorded |
| Phase 1 | NCT00818259 Comparator | Feb 2009 → Jan 2014 | chemotherapy-induced toxicity | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT00819039 Comparator | Jan 2009 → Mar 2013 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00871910 Background | Oct 2006 → Feb 2010 | non-Hodgkin lymphoma, plasma cell myeloma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00648804 Comparator | Jul 2005 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT07706348 Comparator | Jun 2026 → Jul 2027 expected | — | Assiut University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05402553 Comparator | Apr 2022 → Jun 2023 | infectious disease with sepsis | Noha Mansour | Unknown | No outcome recorded |
| Phase 1/2 | NCT04209595 Background | Apr 2020 → Aug 2021 | small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT02858310 Background | Jan 2017 → Jul 2025 | cervical intraepithelial neoplasia, human papilloma virus infection, in situ carcinoma, vulvar neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01801475 Comparator | Jan → May 2013 | — | Stanford University | Completed | No outcome recorded |
| Phase 248 trials | ||||||
| Phase 2 | NCT07455955 Background | Mar 2026 → Jun 2027 expected | breast cancer | Chinese University of Hong Kong | Recruiting | No outcome recorded |
| Phase 2 | NCT07668700 Background | Dec 2025 → Jun 2026 | — | Hameed Latif Hospital, Lahore | Completed | No outcome recorded |
| Phase 2 | NCT07246070 Background | Dec 2025 → Aug 2026 overdue | chemotherapy-induced toxicity | Aiping Zhou | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06904235 Comparator | Jul 2025 → Oct 2027 expected | chemotherapy-induced toxicity | Helsinn Healthcare SA | Recruiting | No outcome recorded |
| Phase 2 | NCT06475846 Comparator | Jun → Oct 2024 | — | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT06241547 Background | Feb 2024 → Jan 2026 | — | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 2 | NCT06428084 Comparator | Nov 2023 → Feb 2024 | gallbladder disorder | Padjadjaran University | Completed | No outcome recorded |
| Phase 2 | NCT05755737 Comparator | Jun 2023 → Dec 2025 overdue | syncope, familial vasovagal | University of Calgary | Recruiting | No outcome recorded |
| Phase 2 | NCT06017167 Comparator | Sep 2022 → Sep 2023 | gallbladder disorder | Tanta University | Unknown | No outcome recorded |
| Phase 2 | NCT04508400 Background | Aug 2022 → Jun 2023 | childhood malignant neoplasm | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 2 | NCT05098067 Background | May → Oct 2022 | hyperemesis gravidarum | Women and Infants Hospital of Rhode Island | Completed | No outcome recorded |
| Phase 2 | NCT04743661 Background | Apr 2022 → Mar 2026 overdue | ependymoma, medulloblastoma | Pediatric Brain Tumor Consortium | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04167813 Comparator | Oct 2021 → Aug 2024 | Lewy body dementia | University College, London | Unknown | No outcome recorded |
| Phase 2 | NCT03237611 Background | Oct 2018 → Feb 2021 | chemotherapy-induced toxicity | Albert Einstein College of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT03642964 Background | Sep 2018 → Dec 2025 overdue | major depressive disorder | Chase Therapeutics Corporation | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03478605 Background | May 2018 → May 2019 | chemotherapy-induced toxicity | Blokhin's Russian Cancer Research Center | Unknown | No outcome recorded |
| Phase 2 | NCT03448068 Background | Apr 2018 → Jan 2020 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT02991456 Comparator | Oct 2017 → May 2022 | chemotherapy-induced toxicity | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT03254459 Background | Sep → Nov 2017 | — | INSYS Therapeutics Inc | Completed | No outcome recorded |
| Phase 2 | NCT02732015 Background | Oct 2016 → Jul 2020 | sarcoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT03134612 Comparator | Jul → Sep 2016 | — | Indonesia University | Completed | No outcome recorded |
| Phase 2 | NCT02581839 Background | Nov 2015 → Jul 2018 | breast cancer, metastatic malignant neoplasm in the brain | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02234466 Comparator | Aug 2014 → Mar 2015 | breast cancer | University of Manitoba | Unknown | No outcome recorded |
| Phase 2 | NCT01450826 Comparator | Jun 2014 → Apr 2017 | glioma | Katy Peters | Completed | No outcome recorded |
| Phase 2 | NCT01857232 Background | Oct 2013 → Feb 2015 | — | Acacia Pharma Ltd | Completed | No outcome recorded |
| Phase 2 | NCT01732458 Comparator | Feb 2013 → Sep 2016 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT01719042 Comparator | Jan → Mar 2013 | Mycobacterium avium complex disease | University of Florida | Withdrawn | No outcome recorded |
| Phase 2 | NCT01697579 Background | Dec 2012 → Nov 2016 | chemotherapy-induced toxicity | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT01691690 Background | Oct 2012 → Nov 2015 | tonsillitis | Nationwide Children's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01740401 Background | Oct 2012 → Dec 2013 | melanoma | Icahn School of Medicine at Mount Sinai | Terminated | No outcome recorded |
| Phase 2 | NCT01507194 Comparator | Feb → Aug 2012 | — | Accenture | Completed | No outcome recorded |
| Phase 2 | NCT01602029 Comparator | Aug 2010 → Jun 2013 | schizoaffective disorder, schizophrenia, schizophreniform disorder | Pakistan Institute of Living and Learning | Completed | No outcome recorded |
| Phase 2 | NCT00954941 Background | Nov 2009 → Apr 2013 | acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00970905 Background | Oct 2009 → Jul 2016 | — | University of Vermont | Completed | No outcome recorded |
| Phase 2 | NCT00967499 Comparator | Jul → Dec 2009 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00539721 Comparator | Oct 2007 → Jul 2008 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00429702 Background | Oct 2007 → Aug 2009 | childhood malignant neoplasm | University of South Florida | Terminated | No outcome recorded |
| Phase 2 | NCT00609765 Background | Aug 2007 → Mar 2008 | malignant pancreatic neoplasm | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00324467 Comparator | Aug 2006 → Dec 2021 | diffuse large B-cell lymphoma | British Columbia Cancer Agency | Unknown | No outcome recorded |
| Phase 2 | NCT00711555 Background | Nov 2005 → Nov 2008 | — | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase 2 | NCT01031498 Comparator | Sep 2005 → Sep 2009 | acute myeloid leukemia, chemotherapy-induced toxicity | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00590317 Comparator | Mar 2005 → Sep 2008 | — | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT00169572 Background | Feb 2005 → ? | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00104403 Background | Dec 2004 → Jan 2006 | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00108095 Background | Oct 2004 → Aug 2005 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00003817 Background | Oct 1999 → Jul 2001 | cancer of unknown primary site | Gary Morrow | Completed | No outcome recorded |
| Phase 2 | NCT00001337 Background | May 1993 → May 2024 | Burkitt lymphoma, anaplastic large cell lymphoma, mediastinal gray zone lymphoma, primary mediastinal large B-cell lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01952886 Comparator | ? → Sep 2014 | malignant glioma | Duke University | Withdrawn | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT06727201 Comparator | Jan 2025 → Dec 2026 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06382012 Comparator | Nov 2024 → Mar 2027 expected | — | Montefiore Medical Center | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06390787 Comparator | Jan → Apr 2024 | — | University of Baghdad | Completed | No outcome recorded |
| Phase 2/3 | NCT05418244 Comparator | Apr 2022 → Jun 2026 overdue | — | State University of New York at Buffalo | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03367988 Background | Dec 2018 → Jan 2023 | drug dependence | University of South Florida | Unknown | No outcome recorded |
| Phase 2/3 | NCT03530007 Comparator | May → Aug 2018 | benign shuddering attacks | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03606369 Comparator | Nov 2015 → Jul 2018 | breast neoplasm | National Cancer Institute of Mexico | Unknown | No outcome recorded |
| Phase 354 trials | ||||||
| Phase 3 | NCT07124195 Background | Aug 2025 → Oct 2026 expected | cancer, chemotherapy-induced toxicity | The First Affiliated Hospital of Xinxiang Medical College | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06861010 Comparator | Mar 2025 → Dec 2026 expected | pancreas disorder | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT05657925 Comparator | Dec 2024 → Dec 2026 expected | syncope, familial vasovagal | University of Calgary | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06007586 Background | May 2024 → Jun 2025 | cervical cancer, endometrial cancer, fallopian tube cancer, ovarian cancer | Sichuan Cancer Hospital and Research Institute | Completed | No outcome recorded |
| Phase 3 | NCT04606264 Comparator | May 2023 → Mar 2025 | — | Jennifer Holder-Murray | Completed | No outcome recorded |
| Phase 3 | NCT05439798 Comparator | Jun 2022 → Apr 2023 | — | Selcuk University | Unknown | No outcome recorded |
| Phase 3 | NCT05346731 Background | Apr 2022 → Mar 2024 | chemotherapy-induced toxicity | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Unknown | No outcome recorded |
| Phase 3 | NCT05244577 Comparator | Jan 2022 → Dec 2023 | malignant testicular germ cell tumor | Shi Yanxia | Unknown | No outcome recorded |
| Phase 3 | NCT05065567 Comparator | Aug 2021 → Nov 2023 | cyclic vomiting syndrome | Corewell Health South | Terminated | No outcome recorded |
| Phase 3 | NCT04144933 Background | May 2021 → Jul 2024 | paralytic ileus | University of Saskatchewan | Unknown | No outcome recorded |
| Phase 3 | NCT04872270 Comparator | Apr 2021 → Apr 2022 | arthropathy | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| Phase 3 | NCT04503668 Background | Dec 2020 → Jan 2024 | female reproductive organ cancer | University of Michigan Rogel Cancer Center | Terminated | No outcome recorded |
| Phase 3 | NCT04536558 Comparator | Oct 2020 → Feb 2021 | chemotherapy-induced toxicity | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT04437017 Comparator | Feb 2020 → May 2022 | chemotherapy-induced toxicity | Fifth Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
| Phase 3 | NCT03931863 Comparator | May 2019 → May 2022 | hypotensive disorder | Aretaieion University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04075955 Background | Apr → Dec 2019 | chemotherapy-induced toxicity | CR-CSSS Champlain-Charles-Le Moyne | Completed | No outcome recorded |
| Phase 3 | NCT03876938 Background | Mar 2019 → Aug 2020 | — | Mahidol University | Unknown | No outcome recorded |
| Phase 3 | NCT04613726 Comparator | Dec 2018 → Dec 2019 | hypotensive disorder | Ataturk University | Completed | No outcome recorded |
| Phase 3 | NCT03578081 Background | Nov 2018 → Nov 2021 | cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT02987985 Background | Oct 2017 → Sep 2019 | obstructive sleep apnea syndrome, respiratory underresponsiveness to hypoxia and hypercapnia | University of Saskatchewan | Completed | No outcome recorded |
| Phase 3 | NCT03219710 Background | Jul 2017 → Jul 2019 | chemotherapy-induced toxicity | All India Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT03079219 Background | Mar 2017 → Mar 2021 | breast cancer | CCTU | Completed | No outcome recorded |
| Phase 3 | NCT03022240 Background | Jan 2017 → Sep 2019 | — | University of Calgary | Completed | No outcome recorded |
| Phase 3 | NCT02979548 Background | Nov 2016 → Jun 2018 | acute myeloid leukemia, chemotherapy-induced toxicity | Dr Atul Sharma | Unknown | No outcome recorded |
| Phase 3 | NCT02735343 Background | Aug 2016 → May 2017 | headache disorder | Mike O'Callaghan Military Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT04140058 Comparator | Jan 2016 → Jan 2017 | hypotensive disorder | University of Jordan | Completed | No outcome recorded |
| Phase 3 | NCT02601027 Background | Nov 2015 → Sep 2019 | female breast carcinoma | Stanford University | Completed | No outcome recorded |
| Phase 3 | NCT02519842 Background | Sep 2015 → Feb 2017 | chemotherapy-induced toxicity | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT02116530 Background | Aug 2014 → Apr 2015 | cancer of unknown primary site, hematopoietic and lymphoid cell neoplasm | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT02830906 Comparator | Apr 2014 → Feb 2015 | — | Thammasat University | Completed | No outcome recorded |
| Phase 3 | NCT02106494 Comparator | Mar 2014 → May 2015 | chemotherapy-induced toxicity | Heron Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT01942343 Comparator | Oct 2013 → Oct 2015 | drug-induced akathisia | University Hospital, Strasbourg, France | Completed | No outcome recorded |
| Phase 3 | NCT02658721 Background | Jan → Jun 2013 | — | Bagcilar Training and Research Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01594749 Background | Sep 2012 → Nov 2014 | chemotherapy-induced toxicity | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01661335 Background | Jun 2012 → Jun 2017 | childhood malignant neoplasm | University of Oklahoma | Completed | No outcome recorded |
| Phase 3 | NCT01362530 Background | Sep 2011 → Mar 2013 | chemotherapy-induced toxicity | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01442376 Comparator | Sep 2011 → Oct 2012 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 3 | NCT01536691 Comparator | Jun 2011 → Nov 2012 | cancer | Hallym University Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT01395901 Comparator | Jun 2011 → Mar 2012 | — | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 3 | NCT01297010 Comparator | Mar → Jul 2011 | — | Instituto Materno Infantil Prof. Fernando Figueira | Completed | No outcome recorded |
| Phase 3 | NCT01121042 Comparator | Jul 2010 → Aug 2018 | schizophrenia | Bayside Health | Completed | No outcome recorded |
| Phase 3 | NCT00891761 Comparator | Sep 2009 → Jul 2010 | cancer, chemotherapy-induced toxicity | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 3 | NCT00971399 Comparator | Sep 2009 → Feb 2011 | chemotherapy-induced toxicity | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01679093 Comparator | Jun 2009 → Jan 2011 | — | University Hospital, Lille | Completed | No outcome recorded |
| Phase 3 | NCT01052844 Comparator | Jan 2009 → Jul 2010 | cisplatin toxicity | Faculdade de Medicina do ABC | Completed | No outcome recorded |
| Phase 3 | NCT00601172 Background | Mar 2008 → Apr 2009 | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00619359 Background | Feb 2008 → Jun 2009 | chemotherapy-induced toxicity | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00337727 Background | Jan 2007 → Oct 2008 | chemotherapy-induced toxicity | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00431236 Background | Nov 2006 → Oct 2007 | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00547989 Comparator | Oct 2006 → Dec 2010 | breast cancer | Maastricht University Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00366834 Background | Jul 2006 → Oct 2007 | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00231777 Comparator | Jul → Nov 2005 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00080444 Background | Apr 2004 → Sep 2006 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00016380 Background | Feb 2001 → Apr 2004 | cancer | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 471 trials | ||||||
| Phase 4 | NCT07639723 Background | Jul 2026 → Jul 2027 expected | — | Endeavor Health | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07088601 Comparator | Aug → Dec 2025 overdue | benign shuddering attacks | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06886230 Comparator | Mar → Jun 2025 | — | Hafiz Muhammad Hamza | Completed | No outcome recorded |
| Phase 4 | NCT05956899 Comparator | Jun 2023 → Mar 2024 | idiopathic scoliosis | University of Malaya | Completed | No outcome recorded |
| Phase 4 | NCT05692245 Comparator | Mar 2023 → Apr 2024 | — | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT05006638 Comparator | Dec 2022 → Jun 2023 | poisoning | Aya Sabry Mohamed Mohamed | Unknown | No outcome recorded |
| Phase 4 | NCT05514483 Comparator | Nov 2022 → Mar 2024 | acute respiratory distress syndrome | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | Unknown | No outcome recorded |
| Phase 4 | NCT05299866 Background | Apr 2022 → May 2024 | — | Ling Dong | Unknown | No outcome recorded |
| Phase 4 | NCT05265507 Comparator | Mar 2022 → May 2023 | — | The Second Affiliated Hospital of Chongqing Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT05221151 Comparator | Jan → May 2022 | anxiety | Menoufia University | Completed | No outcome recorded |
| Phase 4 | NCT04785118 Comparator | Oct 2021 → Dec 2022 | — | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT05172739 Comparator | Oct 2021 → Nov 2025 overdue | chronic pain syndrome, non-small cell lung carcinoma, substance-related disorder | University of Crete | Recruiting | No outcome recorded |
| Phase 4 | NCT04983498 Background | Sep → Dec 2021 | — | Northwestern University | Withdrawn | No outcome recorded |
| Phase 4 | NCT04766996 Background | May → Dec 2021 | substance-related disorder | Emory University | Terminated | No outcome recorded |
| Phase 4 | NCT04764344 Comparator | Apr 2021 → May 2023 | — | Western Michigan University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT04817189 Comparator | Feb 2021 → Jul 2024 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 4 | NCT04240626 Background | Jan 2021 → Jun 2026 overdue | morbid obesity | University of California, Davis | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04870541 Comparator | Dec 2020 → Jun 2021 | benign shuddering attacks | Saint-Joseph University | Unknown | No outcome recorded |
| Phase 4 | NCT04576390 Comparator | Oct 2020 → Apr 2021 | — | Theodor Bilharz Research Institute | Unknown | No outcome recorded |
| Phase 4 | NCT04654429 Comparator | Oct 2020 → Dec 2022 | movement disorder | University of Malaya | Unknown | No outcome recorded |
| Phase 4 | NCT04894864 Comparator | Oct 2020 → Sep 2026 expected | abdominal aortic aneurysm | University of Crete | Recruiting | No outcome recorded |
| Phase 4 | NCT04509258 Comparator | Oct 2020 → Oct 2021 | — | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT04745273 Comparator | Sep 2020 → Jun 2021 | — | Acibadem University | Completed | No outcome recorded |
| Phase 4 | NCT04150614 Comparator | May 2020 → Jul 2026 overdue | chemotherapy-induced toxicity | University of Illinois at Chicago | Recruiting | No outcome recorded |
| Phase 4 | NCT04248179 Comparator | Nov 2019 → Dec 2021 | ductal breast carcinoma in situ | Zealand University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04365686 Background | Apr 2019 → Apr 2020 | — | Fayoum University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03973411 Comparator | Mar 2019 → Mar 2020 | hypotensive disorder | Hospital de Base | Unknown | No outcome recorded |
| Phase 4 | NCT03831633 Comparator | Sep 2018 → Jul 2019 | — | VIFORFRANCE | Unknown | No outcome recorded |
| Phase 4 | NCT03467750 Background | Jul 2018 → Aug 2023 | obstructive sleep apnea syndrome | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT03862391 Comparator | Jun 2018 → Nov 2019 | acute stress disorder | Sakarya University | Completed | No outcome recorded |
| Phase 4 | NCT03435003 Background | Aug 2017 → Mar 2019 | — | Stony Brook University | Completed | No outcome recorded |
| Phase 4 | NCT03629522 Comparator | Aug → Nov 2017 | — | University Hospital, Mahdia | Completed | No outcome recorded |
| Phase 4 | NCT03239210 Comparator | Jun 2017 → May 2022 | Tourette syndrome, obsessive-compulsive disorder | NYU Langone Health | Completed | No outcome recorded |
| Phase 4 | NCT03056482 Comparator | May 2017 → Jun 2019 | cannabis dependence | Dr. Marco L.A. Sivilotti | Completed | No outcome recorded |
| Phase 4 | NCT03152955 Background | May 2017 → May 2018 | trigeminal neuralgia | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 4 | NCT03421860 Comparator | Feb 2017 → Feb 2018 | heart failure | University Tunis El Manar | Completed | No outcome recorded |
| Phase 4 | NCT02953210 Background | Nov 2016 | neuropathy, painful, paralytic ileus | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT03075163 Comparator | Oct 2016 → Apr 2017 | — | University of California, Davis | Terminated | No outcome recorded |
| Phase 4 | NCT02913768 Comparator | Oct 2016 → Sep 2017 | hypotensive disorder | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT02657031 Background | Mar 2016 → Mar 2017 | headache disorder | University Medical Center of Southern Nevada | Completed | No outcome recorded |
| Phase 4 | NCT02760069 Comparator | Jan 2016 → Nov 2017 | — | Brooke Army Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02959840 Comparator | Jul 2015 → Mar 2016 | — | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 4 | NCT02441894 Background | Apr 2015 → Feb 2016 | prostate cancer | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02386059 Comparator | Mar → Aug 2015 | — | University of Catania | Unknown | No outcome recorded |
| Phase 4 | NCT02327923 Comparator | Jan 2015 → Feb 2016 | gallstones | B.P. Koirala Institute of Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02724033 Comparator | May 2014 → Sep 2018 | — | Indiana University | Terminated | No outcome recorded |
| Phase 4 | NCT02296333 Comparator | May → Nov 2014 | — | Mustafa Kemal University | Completed | No outcome recorded |
| Phase 4 | NCT02085577 Background | May 2014 → Oct 2015 | chronic pain syndrome | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT02110719 Comparator | Mar 2014 → Jul 2015 | constipation disorder | Hartford Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02082678 Comparator | Feb 2014 → May 2018 | alcohol-related disorders, bipolar disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01896440 Comparator | Oct 2013 | childhood malignant neoplasm | University of Oklahoma | Withdrawn | No outcome recorded |
| Phase 4 | NCT01933542 Comparator | Aug 2013 → Aug 2015 | — | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT01868425 Comparator | Apr 2013 → Dec 2017 | — | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 4 | NCT01636947 Background | Dec 2012 → Aug 2014 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT01953978 Comparator | Dec 2012 → Aug 2014 | — | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 4 | NCT01837394 Comparator | Aug 2012 → Jun 2013 | — | Jens Borglum Neimann | Completed | No outcome recorded |
| Phase 4 | NCT01659775 Comparator | Aug 2011 → Nov 2012 | chemotherapy-induced toxicity | LG Life Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02021851 Comparator | Jul 2011 → Jul 2012 | — | Yeditepe University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01819857 Comparator | Jun 2011 → Jul 2013 | early repolarization associated with ventricular fibrillation | Medical University of Gdansk | Completed | No outcome recorded |
| Phase 4 | NCT01007500 Comparator | Sep 2009 → Jul 2010 | — | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT01434017 Comparator | Nov 2008 → Jun 2013 | — | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase 4 | NCT02143531 Comparator | Sep 2008 → Aug 2012 | — | American University of Beirut Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00738621 Comparator | Jul 2008 → Aug 2010 | — | Scott and White Hospital & Clinic | Completed | No outcome recorded |
| Phase 4 | NCT00659945 Comparator | Jun 2008 → Nov 2009 | — | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00588835 Comparator | Mar 2008 → Jan 2010 | neoplasm | Radboud University Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT00825071 Comparator | Nov 2007 → Mar 2008 | — | University of Jordan | Completed | No outcome recorded |
| Phase 4 | NCT00734929 Comparator | Sep 2007 → Jun 2009 | — | Duke University | Completed | No outcome recorded |
| Phase 4 | NCT01474915 Comparator | Jun 2007 → Dec 2012 | — | Sergio Bergese | Completed | No outcome recorded |
| Phase 4 | NCT01352130 Comparator | Mar → Apr 2007 | — | Tata Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00778011 Comparator | Nov 2005 → Dec 2006 | — | WellSpan Health | Completed | No outcome recorded |
| Phase 4 | NCT00781768 Comparator | Aug 2003 → Oct 2008 | — | Loyola University | Completed | No outcome recorded |
| Phase not applicable62 trials | ||||||
| — | NCT07558226 Comparator | May 2026 → Nov 2027 expected | — | Fundacio Puigvert | Recruiting | No outcome recorded |
| — | NCT05784350 Comparator | Aug 2025 → May 2028 expected | — | Meir Medical Center | Not yet recruiting | No outcome recorded |
| — | NCT07084753 Comparator | Jul → Sep 2025 overdue | obesity disorder | IVO JURISIC | Not yet recruiting | No outcome recorded |
| — | NCT07037654 Comparator | Jun 2025 → Jul 2026 overdue | — | Suez Canal University | Active not recruiting | No outcome recorded |
| — | NCT06850740 Comparator | Mar → Jun 2025 overdue | — | Suez Canal University | Enrolling by invitation | No outcome recorded |
| — | NCT06810882 Comparator | Feb 2025 → Feb 2027 expected | — | Tanta University | Recruiting | No outcome recorded |
| — | NCT07087925 Comparator | Jan → Apr 2025 | — | Rully Riyandika | Completed | No outcome recorded |
| — | NCT06795594 Background | Jan → Mar 2025 | — | Beijing Tongren Hospital | Completed | No outcome recorded |
| — | NCT06656299 Background | Oct 2024 → Nov 2025 overdue | acute cholecystitis, cholelithiasis | Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital | Recruiting | No outcome recorded |
| — | NCT06625632 Background | Oct 2024 → Jan 2025 overdue | hyperemesis gravidarum | Cairo University | Not yet recruiting | No outcome recorded |
| — | NCT06343753 Comparator | May 2024 → May 2025 | neuropathy, painful | Ain Shams University | Completed | No outcome recorded |
| — | NCT06437236 Comparator | Apr → Dec 2024 | — | Sohag University | Unknown | No outcome recorded |
| — | NCT06930456 Comparator | Mar 2024 → Mar 2025 overdue | hypotensive disorder | Nada kamel Elgamal | Enrolling by invitation | No outcome recorded |
| — | NCT07568938 Comparator | Jan 2024 → Feb 2027 expected | obesity disorder, substance-related disorder | G.Gennimatas General Hospital | Recruiting | No outcome recorded |
| — | NCT06153602 Background | Dec 2023 → Nov 2024 | — | Chulalongkorn University | Completed | No outcome recorded |
| — | NCT05881486 Comparator | Jun 2023 | respiratory system disorder | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| — | NCT05317611 Comparator | Jul 2022 → Jan 2025 | — | Zagazig University | Completed | No outcome recorded |
| — | NCT05137288 Comparator | Dec 2021 → May 2022 | — | Sohag University | Unknown | No outcome recorded |
| — | NCT04191694 Background | Oct 2019 → Mar 2020 | — | Coombe Women and Infants University Hospital | Unknown | No outcome recorded |
| — | NCT03023462 Comparator | Sep 2019 → Jun 2020 | — | Ostfold Hospital Trust | Completed | No outcome recorded |
| — | NCT03603119 Comparator | May 2018 → Nov 2019 | — | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT06609993 Background | Dec 2017 → Mar 2020 | abdominal aortic aneurysm | Michał Stasiowski | Completed | No outcome recorded |
| — | NCT03653520 Comparator | Jun → Nov 2017 | cataract | Avanti Anesthesia | Completed | No outcome recorded |
| — | NCT03141645 Comparator | Jun 2017 → Dec 2018 | — | Siriraj Hospital | Completed | No outcome recorded |
| — | NCT03117894 Comparator | May 2017 → Oct 2020 | breast cancer | Umeå University | Completed | No outcome recorded |
| — | NCT03202459 Comparator | Mar → Sep 2017 | — | Faculdade de Ciências Médicas da Santa Casa de São Paulo | Unknown | No outcome recorded |
| — | NCT02618343 Comparator | Oct 2016 → Mar 2019 | — | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| — | NCT02625181 Background | Jul 2016 → Nov 2017 | — | Vanderbilt University | Completed | No outcome recorded |
| — | NCT02473042 Background | Mar 2016 → Nov 2024 | breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| — | NCT02460055 Comparator | Mar → Jun 2016 | lung disorder | Baylor College of Medicine | Withdrawn | No outcome recorded |
| — | NCT02456662 Comparator | Oct 2015 → Apr 2019 | — | University of Rochester | Completed | No outcome recorded |
| — | NCT04500249 Background | Oct 2015 → Oct 2020 | carotid stenosis | Medical University of Silesia | Unknown | No outcome recorded |
| — | NCT03017222 Comparator | Sep 2015 → Apr 2016 | — | Yonsei University | Completed | No outcome recorded |
| — | NCT03041935 Background | Sep 2015 → Jan 2019 | cryptorchidism | Alberta Children's Hospital | Completed | No outcome recorded |
| — | NCT03041948 Background | Sep 2015 → Sep 2018 | — | Alberta Children's Hospital | Unknown | No outcome recorded |
| — | NCT02288923 Comparator | Mar 2015 → Jul 2018 | osteoarthritis, knee | Royal Devon and Exeter NHS Foundation Trust | Completed | No outcome recorded |
| — | NCT02194192 Comparator | Jul 2014 → Mar 2015 | — | Mahidol University | Completed | No outcome recorded |
| — | NCT02408146 Background | Jan 2014 → Jul 2015 | neuropathy, painful | First Affiliated Hospital of Harbin Medical University | Unknown | No outcome recorded |
| — | NCT01912807 Comparator | Dec 2013 → Sep 2014 | — | University of Saskatchewan | Completed | No outcome recorded |
| — | NCT01993238 Background | Nov 2013 → Jan 2014 | — | Solta Medical | Completed | No outcome recorded |
| — | NCT01393288 Comparator | Nov 2013 → Nov 2014 | — | University of California, San Francisco | Withdrawn | No outcome recorded |
| — | NCT01952626 Comparator | Apr 2013 → Jun 2014 | poisoning | Kyungpook National University Hospital | Completed | No outcome recorded |
| — | NCT01566838 Comparator | Oct 2012 → Dec 2015 | — | Inova Health Care Services | Completed | No outcome recorded |
| — | NCT01669213 Comparator | Aug → Dec 2012 | hypotensive disorder | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT01859715 Comparator | Jun 2012 → Jan 2013 | — | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT01511627 Comparator | Jan → Jul 2012 | — | University of Saskatchewan | Withdrawn | No outcome recorded |
| — | NCT01510379 Background | Aug 2011 → Jul 2012 | — | Kyle A Perry | Completed | No outcome recorded |
| — | NCT03435692 Background | Jul 2011 → Jul 2014 | — | Seattle Children's Hospital | Terminated | No outcome recorded |
| — | NCT01739985 Background | Dec 2010 → Jul 2013 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| — | NCT00757822 Comparator | Dec 2009 → Dec 2013 | — | VA Office of Research and Development | Completed | No outcome recorded |
| — | NCT02038894 Comparator | Dec 2009 → Nov 2013 | eosinophilic esophagitis | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| — | NCT00918190 Comparator | Jun 2009 → Dec 2010 | — | King Khaled Eye Specialist Hospital | Completed | No outcome recorded |
| — | NCT00691275 Comparator | Sep 2008 → Sep 2009 | gastroenteritis | Children's Hospitals and Clinics of Minnesota | Withdrawn | No outcome recorded |
| — | NCT00699894 Comparator | Jun → Sep 2008 | — | Northwell Health | Withdrawn | No outcome recorded |
| — | NCT00651755 Background | Mar 2008 → Sep 2011 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| — | NCT00624208 Comparator | Feb 2008 → Aug 2009 | early repolarization associated with ventricular fibrillation | University of British Columbia | Completed | No outcome recorded |
| — | NCT00655642 Comparator | Mar 2007 → Oct 2008 | — | Vanderbilt University | Terminated | No outcome recorded |
| — | NCT00641797 Comparator | Nov 2006 → Dec 2010 | benign paroxysmal positional vertigo | Lehigh Valley Hospital | Completed | No outcome recorded |
| — | NCT00343863 Comparator | Jan 2006 → Dec 2010 | male breast carcinoma | University of Washington | Completed | No outcome recorded |
| — | NCT00137202 Comparator | Jun 2005 → May 2006 | — | United States Army Institute of Surgical Research | Completed | No outcome recorded |
| — | NCT00248547 Comparator | May 2004 → Jan 2009 | cancer | OHSU Knight Cancer Institute | Completed | No outcome recorded |
| — | NCT00005994 Background | Aug 2000 → Jul 2001 | cancer of unknown primary site | University of Rochester | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2007-06-26 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval Of Ondansetron Hcl Tablets And Ondansetron Orally Disintegrating Tablets USP tevapharm.com ↗ |
| 2006-02-26 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval of Ondansetron Injection USP tevapharm.com ↗ |
Evidence & citations 43 cited values
Every value below carries the sentence it was read from. 456 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ondansetron | “METHODS: Women scheduled for elective cesarean delivery were randomized to one of three groups: placebo (placebo plus placebo); metoclopramide (metoclopramide 10 mg plus...” PMID 23635626 ↗ Mar 2013437“5HT3 (5-Hydroxytryptamine 3) antagonists (ondansetron, granisetron or tropisetron) used as the local institutional standard of care will be permitted, although the preferential...” NCT01843868 ↗ “Comparing the Effects of Ondansetron Versus Dexamethasone on the Incidence of Post-dural Puncture Headache (PDPH) , Nausea and Vomiting After Spinal Anaesthesia of Parturients...” NCT05202574 ↗ “Placebo, given orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1)...” NCT01052844 ↗ “30 minutes prior to emergence 0.2 μg/kg total body weight Sufentanil IV and 1 gram of paracetamol IV (if 6hrs since preoperative medicine) and 4 mg ondansetron IV (PONV...” NCT04248179 ↗ “Anesthesia will be maintained with Sevoflurane, Magnesium, Lidocaine, Ketamine, Decadron, Ondansetron, and Ketorolac at a concentration range/dose(s) based on the clinical need...” NCT03367988 ↗ “Day 1: Aprepitant 125mg QD (once daily); Ondansetron 8mg BD (twice daily); Dexamethasone 12mg QD (Aprepitant, Ondansetron and Dexamethasone to be take 60 minutes before...” NCT07455955 ↗ “Granisetron Transdermal Delivery System (GTDS) efficacy compared with the ondansetron efficacy with regard to Complete Response (CR) of Chemotherapy Induced Nausea and Vomiting (CINV).” NCT01659775 ↗ “Pramipexole group: Consenting individuals meeting accession criteria will start pramipexole 2.0mg daily dose (1.0mg twice a day) with ondansetron 16mg daily dose (8mg twice a day).” NCT03642964 ↗ “Patients will receive ondansetron (0.1 mg / kg dose of 4mg cap) associated with dexamethasone (0.15 mg / kg dose of 5mg ceiling) or dexamethasone (0.15 mg / kg) or placebo” NCT01297010 ↗ “Comparison Between Propofol, Ondansetron and Pregabalin for Control of Emetic Attacks During Caesarean Delivery With Spinal Anesthesia: Randomized Clinical Trial” NCT06300346 ↗ “To prevent postoperative nausea and vomiting (PONV), patients receive dexamethasone (8 mg), ondansetron (4 mg), and metoclopramide (10 mg) intraoperatively.” NCT07084753 ↗ “Hydration is reduced to 1 hour and 40 minutes and Akynzeo is administered as an oral drug instead of Ondansetron being given as an IV before chemotherapy.” NCT04362449 ↗ “Ondansetron (Ondansetron Accord 2mg/ml, 2 ml solution, Accord Healthcare Limited, Great Britain) in a dose of 4 mg will be administered intravenously” NCT06609993 ↗ “In attempt to prevent hypotension after spinal anesthesia induction, Ondansetron, a serotonin receptor antagonist, has been used effectively” NCT05784350 ↗ “5-HT3-antagonists, including ondansetron, are commonly used as anti-emetics to prevent and treat chemotherapy-induced vomiting and nausea” NCT07706348 ↗ “With Intravenous Antiemetic Drugs Dexamethasone and Ondansetron and Incidence of Post-operative Nausea Vomiting for Inner Ear Surgery” NCT02724033 ↗ “An anti-emetic (e.g., IV ondansetron \[0.25 mg/kg, 16 mg maximum\] or equivalent) will be given as premedication for 131I-omburtamab” NCT04743661 ↗ “Randomized to either the control (pyridostigmine+ placebo) or the test group (pyridostigmine + ondansetron) and treated for 6 weeks.” NCT04226170 ↗ “The pump is established with S-ketamine 1mg/kg, sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml.” NCT05299866 ↗ “dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy aprepitant 80 mg orally D2-4, dexamethasone 8 mg/day orally D2-4” NCT03876938 ↗ “Local infiltration with bupivacaine and Piritramide and Paracetamol as postoperative analgesic, and ondansetron as required” NCT00547989 ↗ “Test group 1 (OCA group):oxycodone 1mg/kg + flurbiprofen 50mg + ondansetron 16mg + 0.9% normal saline diluted to 100ml” NCT05742256 ↗ “The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery” NCT03202459 ↗ “Pre-operatively, all patients will receive Ondansetron 4 mg IV, and metoclopramide 10 mg intravenously (IV).” NCT06343753 ↗ “rescue intravenous antiemetic medication using 4 mg of ondansetron will be administered by anaesthesiologist” NCT04500249 ↗ “standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane” NCT01868425 ↗ “Participants received droperidol (0.625 or 1.25 mg) or ondansetron 4 mg during general anaesthesia.” PMID 29746373 ↗ Dec 2018 “Patients receive concurrent aprepitant 125mg, dexamethasone 12mg, and ondansetron 8mg p.o. on day1.” NCT03572829 ↗ “intravenous premedication (midazolam 2 mg and 4mg ondansetron) was administered to all patients” NCT04365686 ↗ “During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron will be given.” NCT03467750 ↗ “ondansetron (Zofran) tablets combined with a medicine called dexamethasone given IV” NCT00781768 ↗ “Pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)” NCT01993238 ↗ “Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1)” NCT01290276 ↗ “ondansetron 4mg IV, sugammadex 2mg/kg or 4 mg/kg dose depending on twitch” NCT03448068 ↗ “the patients will be given 4mg dexamethasone and or 4mg ondansetron IV.” NCT02288923 ↗ “either ondansetron (if receiving placebo inhalation) or normal saline)” NCT00285051 ↗ “intravenous ondansetron 8 mg, and intravenous dexamethasone 12 mg” NCT06007586 ↗ “Ondansetron is a medication used to prevent nausea or vomiting.” NCT07697625 ↗ “Ondansetron Injection (administered on Day 1, 8 mg, once daily)” NCT07124195 ↗ “RHB-102 (BEKINDA) (Ondansetron 24 mg Bimodal Release Tablets)” NCT02246439 ↗ “Ondansetron 8mg IV, D1-5 30 minutes before chemotherapy” NCT05244577 ↗ “BEKINDA (Ondansetron 12 mg Bimodal Release Tablets)” NCT02757105 ↗ “Dexketoprofen trometamol, Ondansetron or Droperidol” NCT05172739 ↗ “Dexamethasone 4mg and Ondansetron 4mg intravenously” NCT01511627 ↗ “Ketamine 0.3 mg/kg along with ondansetron 4 mg IV” NCT02735343 ↗ “Ondansetron 16mg orally pre-chemotherapy on day 1” NCT04075955 ↗ “ondansetron hydrochloride(8mg, i.v. day 1-day 3)” NCT04536558 ↗ “along with Ondansetron 4mg or Droperidol 0.625mg” NCT04894864 ↗ “then ondansetron 8 mg IV + esketamine 0.2 mg/kg” NCT07603596 ↗ “intravenous administration of 8 mg ondansetron” NCT01819857 ↗ “Ondansetron: 8-16 mg d1 intravenous or oral” NCT04437017 ↗ “and ondansetron 4mg. Fentanyl will be given” NCT01566838 ↗ “ondansetron 8 mg IV x1. Post-operatively” NCT03330119 ↗ “we will give them 4 mg of ondansetron” NCT03862391 ↗ “8 mg ondansetron IV in 20 mL saline” NCT06289335 ↗ “IV ondansetron 8 mg on Day 1” NCT03831633 ↗ “Ondansetron: 4-8mg IV” NCT07558226 ↗ “4 mg Ondansetron” NCT07568938 ↗ “Ondansetron 4 mg” NCT06625632 ↗ “Ondansetron” NCT02648490 ↗ |
| Known as | A04AA01 | ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗ |
| Known as | AD04 | “AD04 (ondansetron)” NCT04101227 ↗ |
| Known as | BEKINDA | “Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (BEKINDA) (Ondansetron 24 mg Bimodal Release Tablets) for Acute Gastroenteritis.” NCT02246439 ↗1“BEKINDA (Ondansetron 12 mg Bimodal Release Tablets)” NCT02757105 ↗ |
| Known as | Demorem | ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗ |
| Known as | Desmethylondansetron | ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗ |
| Known as | EUR-1025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01036854 ↗ |
| Known as | GR 38032F | ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗ |
| Known as | GR-38032 | ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗ |
| Known as | GR-C507/75 | ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗ |
| Known as | NSC-665799 | ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗ |
| Known as | NSC-757870 | ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗ |
| Known as | Odansetron hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗ |
| Known as | OND | “The combination of dexamethasone (DEX), ondansetron (OND) and droperidol (DRO) is efficacious in preventing postoperative nausea and vomiting in adults, but has not been well...” PMID 28505233 ↗ Jun 2017 |
| Known as | Ond-PR1 | “Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1)” NCT01290276 ↗ |
| Known as | Ond-PR2 | “Single oral dose of 8 mg ondansetron pulsatile-release formulation 2 (Ond-PR2)” NCT01290276 ↗ |
| Known as | Ondalenz | “oral ondansetron in the form of an oral soluble film 4 mg strip (Ondalenz, 4 mg orodispersible films of Nerhadou International Co.)” NCT07088601 ↗5“Pediatric patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery as a study group.” NCT06423820 ↗ “Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.” NCT07489742 ↗ “Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.” NCT06423807 ↗ “Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.” NCT06254131 ↗ “Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.” NCT07511491 ↗ |
| Known as | Ondansetron (as hydrochloride) | ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗ |
| Known as | Ondansetron (Zofran) | “Ondansetron (Zofran)” NCT00781768 ↗1“ondansetron (Zofran)” NCT02724033 ↗ |
| Known as | Ondansetron Accord | “Ondansetron (Ondansetron Accord 2mg/ml, 2 ml solution, Accord Healthcare Limited, Great Britain) in a dose of 4 mg will be administered intravenously” NCT06609993 ↗ |
| Known as | Ondansetron HCl | “Ondansetron HCl 8 mg OD Tablet (test) dosed in first period followed by Zofran® 8 mg ODT (reference) dosed in second period” NCT00934180 ↗2“Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)” NCT00947128 ↗ “Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)” NCT00946387 ↗ |
| Known as | ondansetron hydrochloride | “ondansetron hydrochloride(8mg, i.v. day 1-day 3)” NCT04536558 ↗ |
| Known as | Ondansetron hydrochloride dihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗ |
| Known as | Ondansetron hydrochloride hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗ |
| Known as | Ondansetron hydrochloride preservative free | ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗ |
| Known as | Ondansetron monohydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗ |
| Known as | Ondasetron | “Drug: Ondasetron 4mg” NCT07084753 ↗ |
| Known as | Ondemet | ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗ |
| Known as | RHB-102 | “Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (BEKINDA) (Ondansetron 24 mg Bimodal Release Tablets) for Acute Gastroenteritis.” NCT02246439 ↗ |
| Known as | Setofilm | ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗ |
| Known as | SN 307 | ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗ |
| Known as | ZOFATRONE | “Patients will receive 8 mg of ondansetron (ZOFATRONE®, 8 mg/4 mL, EVA Pharma, Egypt)” NCT06850740 ↗ |
| Known as | Zofran | “Treatment B: single dose of Zofran ODT (containing ondansetron 8 mg) was orally administered, allowed to dissolve, swallowed with saliva, followed with 240 mL room temperature...” NCT01217190 ↗30“Ondansetron HCl 8 mg OD Tablet (test) dosed in first period followed by Zofran® 8 mg ODT (reference) dosed in second period” NCT00934180 ↗ “Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.” NCT01659775 ↗ “ondansetron (Zofran) tablets combined with a medicine called dexamethasone given IV” NCT00781768 ↗ “To compare the single-dose bioavailability of Ondansetron ODT 8 mg and Zofran 8 mg” NCT00653458 ↗ “D1 Zofran 8mg pre-Cyclophosphamide 300mg/mg2 po and D3 Ipilimumab 10mg/kg iv” NCT01740401 ↗ “The usual treatment for nausea/vomiting is a drug called Zofran” NCT03125811 ↗ “ondansetron 4mg (Zofran; GlaxoSmithKline, Alexandria, USA” NCT06017167 ↗ “Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)” NCT00947128 ↗ “Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)” NCT00946387 ↗ “Ondansetron (Zofran)” NCT06727201 ↗ “Ondansetron (Zofran)” NCT00137202 ↗ “ondansetron (Zofran)” NCT00000443 ↗ “Ondansetron (Zofran)” NCT02793843 ↗ “Ondansetron (Zofran)” NCT07639723 ↗ “ondansetron (Zofran)” NCT00027079 ↗ “Ondansetron (Zofran)” NCT07201883 ↗ “Zofran” NCT01691690 ↗ |
| Known as | Zofran (ondansetron hydrochloride) | “Zofran (ondansetron hydrochloride)” NCT01290276 ↗1“Zofran, Ondansetron hydrochloride” NCT05378113 ↗ |
| Known as | zofran - ondansetron | “zofran - ondansetron” NCT01536691 ↗ |
| Known as | Zofran ODT | “Ondansetron HCl with the already marketed reference formulation Zofran ODT under fasting conditions” NCT00934180 ↗1“Single dose of Zofran ODT (containing ondansetron 8 mg) administered without water” NCT01220167 ↗ |
| Known as | Zofran preservative free | ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗ |
| Known as | Zophren | ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗ |
| Known as | Zuplenz | ChEMBL registry synonym — accepted as the source's own label CHEMBL46 ↗ |
| Action | Inhibit | “Serotonin 3a (5-HT3a) receptor antagonist” CHEMBL46 ↗1“a 5HT3 antagonist” NCT00000289 ↗ |
| Modality | Other / unclassified | “Ondansetron is a selective 5-HT3 receptor antagonist.” NCT00967499 ↗ |
| Route | Oral | “ondansetron orally” NCT00005994 ↗ |
| Target | HTR3A | “Serotonin 3a (5-HT3a) receptor antagonist” CHEMBL46 ↗ |